Table 3 Sections of the Allergenius report

1^st section,

1. Headings.

2. Patient’s ID, test date and methodology used.

3. The declaration of the patient’s sensitization (and not allergy) as the unique result generated by the ES report.

4. An overview of the patient’s sensitization (genuine, cross-reactive, inhalant, food, hymenoptera, etc.) and the frequency of such a distribution of sensitization in an uncensored population of allergic patients.

5. Some general statistical data, such as the total ISAC score (in general correlating to the level of circulating total IgE), the fraction of the genuine and cross-reactive components, the fraction of food allergens, etc.

6. An analysis of the compatibility between the ISAC results and the diseases suffered by the patients.

7. The patient’s phenotyping[32]: Type I, only genuine inhalant components; Type II, genuine inhalant components with a few cross-reactive inhalant components; Type III, both genuine and cross-reactive components are represented in the Patient’s IgE profile; Type IV, the IgE profile is constituted almost exclusively of IgE to inhalant cross-reactive components; Type V, sIgE are specific for only food components. This classification seems to be predictive of the immunotherapy outcome[6].

8. Warnings indicating the presence of sIgE directed at potentially dangerous components[8].

2^nd section. The list of positive components.

1. IgE-positive inhalant components are described. For each component, the characteristics listed in the description of the frame structure of Allergenius are reported.

2. Positive food components are reported; in particular, the susceptibility to heat and pH is described.

3. The list of different families of cross-reactive components, which includes many of the above-analyzed components, is reported. The IE performs an analysis of each family, indicating whether sensitization to the single component(s) or to the whole family is suspected.

3^rd section. This section is considered helpful to the doctors while managing patients. It includes:

1. Indications of the relationships between the positive molecular component(s) and known clinical syndrome(s) or associations are listed (Table 3).

2. Some short indication of the therapy[29, 30], including the removal of the allergen immunotherapies for most well-known allergens, such as mites (D1 and D2), grasses (G2 and 6), trees (T3 and T9), weeds (W1, W6, W21) and animals (E1 and E5), or medical therapies with bronchodilators, local steroids, and new-generation anti-histaminic drugs. Note that this is a beta-version and is implemented strictly for research use only.

3. An analysis of the discrepancies between the SPT, sIgE and ISAC results to improve the reading of the complex microarray tests.